FDA Says Goodbye To Its Antiviral Drugs Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency terminates the panel, which has not met since October 2013, after finding it was “no longer needed.” The committee’s activities will be taken up by the anti-infective drugs panel, which has been renamed the Antimicrobial Drugs Advisory Committee.
You may also be interested in...
Center Of Excellence Not Best Model For US FDA Rare Disease Program, Woodcock Says
Center for Drug Evaluation and Research Director says rare disease reviews need multiple specialists, which likely would not fit into a centralized rare disease review group.
In With The Old? 2013 To Mark Rebirth Of CDER’s Pharmacy Compounding, Medical Imaging AdComms
FDA has signaled that it will re-form its Pharmacy Compounding Drugs Advisory Committee, which was dissolved in 2002, as it deals with an ongoing meningitis outbreak related to compounded steroid injections. 2012 proved to be another busy year for the Oncologic Drugs Advisory Committee, but the full drug safety/risk management panel saw a significantly lighter workload than in recent years.
FDA Advisory Committee Line-Up Shrinks With Elimination Of Two Panels
FDA will reduce its total advisory committee count to 30 with the termination of the Pharmacy Compounding and Medical Imaging Drugs Advisory Committees